Kristine Kirtley
Medical · Kingwood, TXNPI 1750493763
Payments from drug & device makers
Across 198 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$706
- Otsuka America Pharmaceutical, Inc.$431
- Lilly USA, LLC$281
- GSK$217
- AbbVie$198
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$156
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,239100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,239 in reported general payments places this provider in the 75th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $124,851 |
| EliquisApixaban | 51 | $48,355 |
| GemtesaVibegron | 32 | $34,249 |
| FarxigaDapagliflozin Propanediol | 40 | $33,483 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $30,598 |
| MounjaroTirzepatide | 23 | $29,627 |
| XareltoRivaroxaban | 12 | $22,115 |
| JardianceEmpagliflozin | 20 | $20,995 |
| JanuviaSitagliptin Phosphate | 17 | $20,057 |
| MyrbetriqMirabegron | 21 | $13,602 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $10,452 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $9,318 |
| Humulin RInsulin Regular, Human | 13 | $3,825 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,018 |
| Levothyroxine Sodium | 284 | $2,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $706 | $124,85180 claims |
| PfizerEliquis | $48 | $48,35551 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $107 | $34,24932 claims |
| AstraZenecaFarxiga | $16 | $33,48340 claims |
| Lilly USA, LLCMounjaro, Humulin N | $281 | $30,78335 claims |
| Boehringer IngelheimJardiance | $50 | $20,99520 claims |
| MerckJanuvia | $45 | $20,05717 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $13,60221 claims |
| GSKBreo Ellipta | $217 | $10,45213 claims |
| AbbVieSynthroid | $198 | $1,88830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,490 medical providers in Texas.
Other medical in Kingwood
- Terry FaleyeKingwood$243K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.